No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Acurx Pharmaceuticals, Inc. (ACXP) stock was $1.31 as of Oct 6, 2026, 12:53 PM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months -71.0% · 3-year avg -65.2%/yr · 5-year avg -57.4%/yr
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections.
Biotechnology · Staten Island, NY
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.45
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.53
vs Estimate
$-0.43
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ACXP | $5.67M | $1.32 | +0.76% | -71.04% | -57.41% | N/A | N/A |
| 2CUPR | $5.68M | $2.12 | -5.78% | -74.72% | N/A | N/A | vs ACXP |
| 3NVNO | $5.77M | $8.30 | +3.62% | -76.55% | -52.99% | N/A | vs ACXP |
| 4SNOA | $5.79M | $1.21 | -0.82% | -69.25% | -59.29% | -47.31% | vs ACXP |
| 5LUCY | $5.86M | $0.93 | +4.47% | -55.10% | N/A | N/A | vs ACXP |
| 6PULM | $5.41M | $1.48 | N/A | -69.44% | -37.13% | -41.91% | vs ACXP |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$17.00
+1187.9% upside
Low
$10.00
Current
$1.32
High
$31.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Quarter ending Dec 2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Quarter ending Mar 2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Quarter ending Jun 2027 | $-0.43 | $-0.43 | $-0.43 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.72 | $-1.72 | $-1.72 | 1 |
| FY 2027 | $-1.50 | $-1.50 | $-1.50 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $276000.00 | $276000.00 | $276000.00 | 3 |
| FY 2027 | $3.54M | $3.54M | $3.54M | 3 |
